CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

Ivarmacitinib

Small moleculeexperimental

Clinical trial activity

31 trials · 18 clinical orgs · 0 marketing orgs

Phase 1
13
Phase 2
14
Phase 3
8
Phase 4
0

Earliest trial started Apr 1, 2015 (NCT02423538)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1nsc(NC(=O)N2C[C@H]3C[C@H](N(C)c4ncnc5[nH]ccc45)C[C@H]3C2)n1
Mol. weight
414.5 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • shr0302

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07266168N/AJan 20, 2026Changxing People's Hospital, First People's Hospital of Hangzhou, Fudan University, Huzhou University, Jiao Tong University, Jinhua Central Hospital, Nanchang University, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo University, Shandong University, Wenzhou Medical University, Zhejiang University
NCT07251595Phase 2Nov 30, 2025Hengrui Therapeutics, Inc.
NCT06925048Phase 2Apr 30, 2025Huazhong University of Science and Technology
NCT06790862Phase 2Feb 11, 2025Hengrui Therapeutics, Inc.
NCT06519526Phase 2Aug 12, 2024Fudan University
NCT07098117Phase 1Jun 19, 2024Hengrui Therapeutics, Inc.
NCT06202612Phase 1Jan 16, 2024Hengrui Therapeutics, Inc.
NCT05900089Phase 1May 30, 2023Henan Medical University
NCT05856058Phase 1May 29, 2023Hengrui Therapeutics, Inc.
NCT05324631Phase 3Aug 16, 2022Hengrui Therapeutics, Inc.
NCT05392127Phase 1Jul 15, 2022Hengrui Therapeutics, Inc.
NCT05404724Phase 1Jun 25, 2022Hengrui Therapeutics, Inc.
NCT05470413Phase 3Apr 18, 2022Reistone Biopharma Company Limited
NCT05181137Phase 3Nov 5, 2021Reistone Biopharma Company Limited
NCT05047341Phase 1Sep 7, 2021Hengrui Therapeutics, Inc.
NCT04875169Phase 3Apr 30, 2021Reistone Biopharma Company Limited
NCT04712838Phase 1Mar 15, 2021Hengrui Therapeutics, Inc.
NCT04717310Phase 2/Phase 3 (Phase 3)Dec 30, 2020Reistone Biopharma Company Limited
NCT04481139Phase 2/Phase 3 (Phase 3)Oct 21, 2020Hengrui Therapeutics, Inc.
NCT04333771Phase 3Jun 30, 2020Hengrui Therapeutics, Inc.
Showing 20 of 31 trials
Page 1 / 2

Organizations

Research & Development (18)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hengrui Therapeutics, Inc.For profit171732015
Reistone Biopharma Company LimitedFor profit9922018
Jiao Tong UniversityAcademic/Hospital3122016
Fudan UniversityAcademic/Hospital2122024
Changxing People's HospitalAcademic/Hospital1012026
Chinese Academy of Medical SciencesAcademic/Hospital1012017
First People's Hospital of HangzhouAcademic/Hospital1012026
Henan Medical UniversityAcademic/Hospital1112023
Huazhong University of Science and TechnologyAcademic/Hospital1112025
Huzhou UniversityAcademic/Hospital1012026
Jinhua Central HospitalAcademic/Hospital1012026
Nanchang UniversityAcademic/Hospital1012026
Ningbo Medical Center Lihuili Eastern HospitalAcademic/Hospital1012026
Ningbo UniversityAcademic/Hospital1012026
Shandong UniversityAcademic/Hospital1012026
Tsinghua UniversityAcademic/Hospital1012016
Wenzhou Medical UniversityAcademic/Hospital1012026
Zhejiang UniversityAcademic/Hospital1112026
18 organizations
Page 1 / 1